Malignant Hyperthermia: Pre- and Post-Dantrolene

A Survey of the Greater Kansas City Area: 1965–1985
  • Mark G. Zukaitis
  • George P. HoechJr.
  • John D. Robinson

Abstract

Malignant hyperthermia (MH) is a rare myogenic hypermetabolic syndrome that is associated with certain commonly used anesthetic agents and muscle relaxants. Although the first case of MH was noted over 60 years ago, the syndrome was not described in the literature until 1960 by Denborough and Lovell.1 Since then, the pathophysiology and etiology have been studied and reviewed extensively. Treatment of MH before 1975 was primarily oriented toward correction of physiologic derangements. Mortality rates were characteristically 60% to 80%. Dantrolene sodium was added to the treatment protocol following successful use in MH-susceptible (MHS) pigs by Harrison2 in 1975 and later that same year in MHS humans by Britt.8 Since its approval by the FDA in 1979 for use in the treatment of MH, dantrolene has led to a dramatic decrease in morbidity and mortality caused by MH. This survey evaluates the pre-dantrolene and post-dantrolene experience with MH in the greater Kansas City area.

Keywords

Iodide Catecholamine Ketamine Isoflurane Halothane 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Denborough MA, Lovell RR (1960) Anaesthetic deaths in a family. Lancet 2:45CrossRefGoogle Scholar
  2. 2.
    Harrison GG (1975) Control of malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth 47:62–65PubMedCrossRefGoogle Scholar
  3. 3.
    Britt BA (1979) Etiology and pathophysiology of malignant hyperthermia. Fed Proc 38:44–48PubMedGoogle Scholar
  4. 4.
    Williams CH (1977) The development of an animal model for the fulminant hyperthermia-stress syndrome, in Henschel EO (ed) Malignant Hyperthermia: Current Concepts. New York: Appleton-Century-Crofts, pp 117–140Google Scholar
  5. 5.
    Ording H (1985) Incidence of malignant hyperthermia in Denmark. Anesth Analg 64: 700–704PubMedGoogle Scholar
  6. 6.
    Wingard DW (1977) Malignant hyperthermia-acute stress syndrome of man? in Henschel EO (ed) Malignant Hyperthermia: Current Concepts. New York: Appleton-Century-Crofts, pp 79–95Google Scholar
  7. 7.
    Williams CH (1976) Some observations on the etiology of fulminant hyperthermia-stress syndrome. Perspect Biol Med 20:120–130PubMedGoogle Scholar
  8. 8.
    Britt BA, Kalow W (1970) Malignant hyperthermia: A statistical review. Can Anaesth Soc J 17: 293–315Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1988

Authors and Affiliations

  • Mark G. Zukaitis
  • George P. HoechJr.
  • John D. Robinson

There are no affiliations available

Personalised recommendations